布埃纳文图拉开采 BVN 深 沪
已收盘 02-06 16:00:00 美东时间
36.95
+1.950
+5.57%
华盛通- 最 高37.72
- 今 开35.77
- 成交量 138.14万股
- 最 低 35.635
- 昨 收 35.00
- 总市值 93.85亿
- 52周最高 41.285
- 市盈率 静 23.31
- 换手率 0.54%
- 52周最低 11.8511
- 委 比 -33.33%
- 总股本 2.54亿
- 历史最高 47.9134
- 量 比 0.64
- 振 幅 5.96%
- 历史最低 2.3896
- 每 手 1
- 风险率 6.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gold, Silver Crash Sparks Mining Meltdown: 10 Stocks Crater On Fed Warsh Shock
Gold fell 9.5% and silver collapsed 27%, sparking a mining stock bloodbath as markets repriced Fed risk after Trump named Kevin Warsh as chair.
01-31 03:48
Trump's 1-Year Mark: Two Country ETFs Crush S&P 500 By Nearly 90%
Under Trump, U.S. equities delivered unspectacular gains in 2025. Investors who looked abroad, however, captured outsized returns.
01-21 04:51
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
2025-11-20 10:28
Scotiabank Maintains Sector Perform on Compania De Minas, Lowers Price Target to $27
Scotiabank analyst Tanya Jakusconek maintains Compania De Minas (NYSE:BVN) with a Sector Perform and lowers the price target from $27.5 to $27.
2025-11-19 22:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Scotiabank Maintains Sector Perform on Compania De Minas, Raises Price Target to $27.5
Scotiabank analyst Tanya Jakusconek maintains Compania De Minas (NYSE:BVN) with a Sector Perform and raises the price target from $27 to $27.5.
2025-11-08 05:03
Buenaventura Mining Co Q3 EPS $0.66 Beats $0.41 Estimate, Sales $431.000M Beat $344.931M Estimate
Buenaventura Mining Co (NYSE:BVN) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.41 by 60.98 percent. This is a 29.03 percent decrease over earnings of $0.93 per share from
2025-10-31 16:08
美股大行评级 | 上调目标价！特斯拉、赛默飞世尔、拉姆研究、波士顿科学、安诺电子、金沙集团等获众多机构评级
今日重点评级关注：摩根士丹利：维持Viking Therapeutics"超配"评级，目标价从98美元升至102美元；摩根大通：维持IDEAYA Biosciences"超配"评级，目标价从74美元升至79美元
2025-10-24 09:51
Buenaventura Announces Q3 2025 Earnings Call
Compania de Minas Buenaventura SAA ( ($BVN) ) has shared an announcement. On Oc...
2025-10-24 05:27
